Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now
- In a volatile market, low-beta picks like VIPS, ALKT, FUTU and VRNA offer investors stability with solid upside potential.
- 07/16/2025
|
What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?
- Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/15/2025
|
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)
- NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Verona Pharma plc (NASDAQ: VRNA ) related to its sale to Merck Sharp & Dohme LLC for $107.00 per American Depository Shares. Is it a fair deal?
- 07/14/2025
|
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
- NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depository Share that they own. KSF is seeking to determine whether this consideration and the process.
- 07/12/2025
|
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
- MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
- 07/11/2025
|
Major deals involving U.S. drugmakers and biotechs over the past decade
- Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
- 07/09/2025
|
Merck to Buy Verona Pharma for Around $10 Billion
- Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
- 07/09/2025
|
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders. Halper Sadeh encourages Verona shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Verona and its.
- 07/09/2025
|
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
- VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
- 07/09/2025
|
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
- Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.
- 07/09/2025
|
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
- Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.
- 07/09/2025
|
Verona Pharma shares jump with Merck set to acquire company in $10 billion deal
- Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to respiratory treatments as the company prepares for a revenue gap following the patent expiry of its cancer blockbuster, Keytruda. This marks Merck's largest transaction since its $10.
- 07/09/2025
|
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
- Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
- 07/09/2025
|
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
- The deal is expected to close in the fourth quarter of 2025.
- 07/09/2025
|
Merck to Buy Verona Pharma in $10 Billion Deal
- Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
- 07/09/2025
|
Merck to acquire Verona Pharma for $10 billion
- Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of its blockbuster cancer drug.
- 07/09/2025
|
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
- RAHWAY, N.J. & RALEIGH, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a tota.
- 07/09/2025
|
Meck looks to soften impact of Keytruda cliff with $10bn tilt for Verona Pharma
- Facing a looming patent cliff on its blockbuster cancer drug Keytruda, Merck & Co Inc (NYSE:MRK, ETR:6MK) is putting the finishing touches to a $10 billion deal to acquire Verona Pharma, a specialist in lung disease therapies, the Financial Times reported. The planned purchase price of $107 per American Depositary Share represents a 35% premium to Verona's most recent Nasdaq close.
- 07/09/2025
|
Best Momentum Stock to Buy for July 7th
- VRNA and EVLV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 7, 2025.
- 07/07/2025
|
New Strong Buy Stocks for July 7th
- PRM, VRNA, SVNDY, TD and MSBHF have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2025.
- 07/07/2025
|
Wall Street Analysts Predict a 25.99% Upside in Verona Pharma (VRNA): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/02/2025
|
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
- New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
- 07/02/2025
|
Here's Why Momentum in Verona Pharma (VRNA) Should Keep going
- Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 07/01/2025
|
Verona Pharma: A Blockbuster Franchise In The Making
- Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projects Verona Pharma's sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide. Global expansion, robust patent protection, and a growing pipeline position Verona for sustained high-margin growth and possible buyout interest.
- 06/10/2025
|
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
- If you want to achieve significant gains in the stock market, you'll probably want to plan to hold on and remain invested for many years, or even decades. But in some cases, big payoffs can come much faster than that.
- 06/05/2025
|
Mizuho's Jared Holz details potential biotech, pharma acquisitions
- Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
- 06/04/2025
|
Verona Pharma Announces June 2025 Investor Conference Participation
- LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:
- 05/21/2025
|
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
- Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population
- 05/06/2025
|
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
- VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favorable, that could impact the performance of the stock.
- 05/01/2025
|
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Olivia Brayer - Cantor Fitzgerald Tara Bancroft - TD Cowen Tiago Fauth - Wells Fargo Thomas Shrader - BTIG Ram Selvaraju - HCW Sushila Hernandez - Van Lanschot Kempen Boobalan Pachaiyappan - ROTH Operator Welcome to Verona Pharma's First Quarter 2025 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
- 04/29/2025
|
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024)
- 04/29/2025
|
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
- Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million.
- 04/07/2025
|
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
- RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450 million on improved terms with funds managed by Oaktree Capital Management, L.P.
- 03/28/2025
|
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operator Good morning ladies and gentlemen. Welcome to the Verona Pharma Fourth Quarter and Full Year 2024 Financial Results and Conference Call.
- 02/27/2025
|
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
- 02/27/2025
|
Verona Pharma Announces March 2025 Investor Conference Participation
- LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:
- 02/18/2025
|
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 02/13/2025
|
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 02/12/2025
|
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)
- Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 01/27/2025
|
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/14/2025
|
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
- Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 01/10/2025
|
Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 01/10/2025
|
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
- Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad label and significant prescriber uptake suggest potential for higher-than-expected peak annual sales. Verona Pharma holds $336 million in cash, projecting operational funding through at least the end of 2026.
- 01/08/2025
|
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
- Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively
- 01/07/2025
|
Verona Pharma Announces December 2024 Investor Conference Participation
- LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
- 11/19/2024
|
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
- Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
- 11/09/2024
|
Verona Pharma to Present at Jefferies London Healthcare Conference
- LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
- 11/05/2024
|
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler. Raghuram Selvaraju - HC Wainwright Tom Shrader - BTIG Edward Thomason - VLK Joon Lee - Truist Boobalan Pachaiyappan - Roth Capital Partners Operator Good morning, everyone, and welcome to Verona Pharma's Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
- 11/04/2024
|
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
- 11/04/2024
|
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
- Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 10/25/2024
|
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
- New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
- 10/24/2024
|
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 10/21/2024
|
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 10/11/2024
|
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
- Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 10/09/2024
|
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
- Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
- 09/30/2024
|
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
- Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effectiveness benchmark of $7,500–$12,700 annually. The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment.
- 09/14/2024
|
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
- Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.
- 09/05/2024
|
Top 3 Health Care Stocks That May Crash In August
- As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
- 08/14/2024
|
Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Group LLC Thomas Shrader - BTIG, LLC Raghuram Selvaraju - H.C. Wainwright & Co. Edward Thomason - Van Lanschot Kempen Operator Welcome to Verona Pharma's Second Quarter 2024 Financial Results and Operating Highlights Conference Call.
- 08/08/2024
|
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.
- 08/08/2024
|
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
- LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST.
- 07/30/2024
|
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
- 07/25/2024
|
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
- Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
- 07/12/2024
|
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
- VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.
- 06/30/2024
|
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
- On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
- 06/27/2024
|
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
- Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
- 06/27/2024
|
US FDA approves Verona Pharma's therapy for 'smoker's lungs'
- The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
- 06/26/2024
|
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
- Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.
- 06/26/2024
|
Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Officer Tara Rheault - Chief Development Officer Conference Call Participants Andrew Tsai - Jefferies Tom Shrader - BTIG Ram Selvaraju - H.C. Wainwright Operator Hello, and welcome to Verona Pharma's First Quarter 2024 Financial Results and Operating Highlights Conference Call.
- 05/09/2024
|
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
- PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.
- 05/09/2024
|
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
- Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities
- 05/09/2024
|
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
- PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces eight posters, including two mini oral symposia, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at the American Thoracic Society International Conference (“ATS”) 2024.
- 05/02/2024
|
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
- 04/25/2024
|
Andrew Fisher Joins Verona Pharma as General Counsel
- LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr.
- 03/04/2024
|
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
- Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.
- 03/01/2024
|
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m. EST / 2:00 p.m.
- 02/29/2024
|
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 02/15/2024
|
Michael Austwick Joins Verona Pharma as Non-Executive Director
- LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.
- 02/01/2024
|
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
- LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
- 01/03/2024
|
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
- Strengthens financial flexibility to support the Company's continued growth Strengthens financial flexibility to support the Company's continued growth
- 01/02/2024
|
3 Stocks That Could Be Monster Winners in 2024
- CRISPR Therapeutics' innovative gene-editing therapy could be a game changer. Madrigal Pharmaceuticals hopes to soon win U.S. approval for a potential blockbuster NASH drug.
- 12/30/2023
|
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
- Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
- 12/22/2023
|
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
- The consensus price target hints at a 135.9% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/23/2023
|
Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment
- Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their main candidate drug, ensifentrine, has shown promising results in clinical trials for COPD, cystic fibrosis, and asthma. The potential market for ensifentrine is significant, with millions of patients worldwide, and it could capture a significant portion of the COPD treatment market.
- 11/18/2023
|
Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
- LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023' at the SCRIP Awards in recognition of his exemplary leadership.
- 11/17/2023
|
Verona Pharma Announces November 2023 Investor Conference Participation
- LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023:
- 11/08/2023
|
Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 119.2% in Verona Pharma PLC American Depositary Share (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 11/07/2023
|
Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer Chris Martin - SVP, Commercial Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Andreas Argyrides - Wedbush Securities Tom Shrader - BTIG Dipesh Patel - H.C. Wainwright Operator Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call.
- 11/04/2023
|
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2023 on Thursday, November 2, 2023 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 10/19/2023
|
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround
- Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 10/04/2023
|
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
- PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces four presentations on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meeting (“CHEST”) 2023.
- 10/03/2023
|
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
- Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4
- 09/06/2023
|
Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon
- Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for COPD, to the FDA. The FDA has a 60-day window to accept or reject the filing, with a potential approval date as early as January 2024. Verona Pharma's commercial strategy includes a swift launch in 1H24, building a sales team, and planning an EU launch by late 2024.
- 09/04/2023
|
Verona Pharma: Financial Health And COPD Market Impact 2024
- Verona Pharma is seeking FDA approval for its COPD treatment, ensifentrine, in 2024. The company has a strong financial position with substantial cash reserves and no immediate need for additional financing. Verona Pharma's ensifentrine has the potential to disrupt the COPD treatment paradigm and carve a niche for itself in the market.
- 08/24/2023
|
Verona Pharma: Targeting The Large COPD Market
- Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for its primary drug candidate that is targeting the large and growing COPD market. The stock has risen impressively since late-stage trial results came out late in 2022. However, insiders have been consistently selling shares in 2023.
- 08/08/2023
|
Verona Pharma plc. (VRNA) Q2 2023 Earnings Call Transcript
- Verona Pharma plc. (NASDAQ:VRNA ) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Christopher Martin - Senior Vice President of Commercial Conference Call Participants Andreas Argyrides - Wedbush Andrew Tsai - Jefferies Edward Nash - Canaccord Genuity Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C.
- 08/05/2023
|
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
- LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that senior management will present a company overview at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 12:00 PM EDT / 5:00 PM BST.
- 07/26/2023
|
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
- 07/20/2023
|
Verona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial Position
- Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel COPD treatment, ensifentrine, exhibiting promise in addressing significant unmet needs in the COPD market. The company's Q1 2023 financial report showcases a robust financial standing, with a cash balance of $291.4 million and a net loss reduction from the previous year.
- 05/28/2023
|
Verona Pharma to Present at Jefferies Healthcare Conference
- LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 AM EDT / 1:00 PM BST.
- 05/24/2023
|
Verona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled Drug
- Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in COPD. Phase 3 data showed that the drug showed a 40% pooled reduction in the rate of exacerbations compared to the placebo.
- 05/18/2023
|
Verona Pharma plc (VRNA) Q1 2023 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer Christopher Martin - Senior Vice President Commercial Conference Call Participants Andreas Argyrides - Wedbush David Risinger - SVB Securities Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Joon Lee - Truist Securities Operator Good morning.
- 05/13/2023
|
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
- 12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4
- 05/02/2023
|
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
- 04/25/2023
|
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
- Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
- 04/16/2023
|
Tech Stocks Are Surging
- The Nasdaq 100 is on a tear
- 03/31/2023
|
Verona's Ensifentrine: A Promising Novel Treatment For COPD Patients
- Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trials show significant improvements in lung function, symptoms, and quality of life for COPD patients.
- 03/27/2023
|
7 Biotech Stocks That Could Be the Next Big Thing
- While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.
- 03/15/2023
|
Verona Pharma: Strong Stock Growth Potential From A Promising New Drug
- Verona Pharma's ensifentrine achieved positive results in a Phase 3 study with an indication for COPD. Ensifentrine is also in Phase 2 studies to address asthma and cystic fibrosis.
- 03/12/2023
|
Verona Pharma plc (VRNA) Q4 2022 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q4 2022 Earnings Conference Call March 7, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer Christopher Martin - Senior Vice President Commercial Conference Call Participants Andreas Argyrides - Wedbush Joon Lee - Truist Securities Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Operator Welcome to Verona Pharma's, Fourth Quarter and Full Year 2022 Financial Results and Operating Highlights Conference Call.
- 03/07/2023
|
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 02/21/2023
|
Verona Pharma: Small Biotech Targeting $10Bn COPD Market With A Late Stage Drug
- Verona Pharma is a UK-based biotech with a $1.6Bn market cap developing a phase 3 asset targeting COPD. Ensifentrine is a novel phase 3 inhaled selective dual inhibitor of PDE3 and PDE4 targeting COPD, which is a $10Bn indication with a high unmet need.
- 02/07/2023
|
Verona: Second Successful Phase 3 Moves The Needle Forward
- Verona Pharma plc's primary endpoint and all key secondary endpoints met in second phase 3 study known as ENHANCE-1; Ensifentrine was used to treat patients with chronic obstructive pulmonary disease. NDA filing of ensifentrine to the FDA for the treatment of patients with chronic obstructive pulmonary disease is expected in the 1st half of 2023, FDA approval possible in 2024.
- 02/01/2023
|
Verona Pharma: Breathing Deeply Could Bring Great Benefits
- Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD.
- 01/13/2023
|
Top 10 Stocks For 2023
- Expect the unexpected has been a common theme over the past two years as global economies and markets reel from a pandemic and the war in Ukraine. June 2022 posted some of the worst performance in decades, with the S&P 500 -21%, DJIA -15%, and trillions erased since 2021 peaks, including big names like Meta, Amazon, and Google.
- 01/05/2023
|
Why These 7 Healthcare Stocks Could Soar in 2023
- With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.
- 01/02/2023
|
4 Drug Stocks That More Than Doubled This Year
- We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
- 12/30/2022
|
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma PLC American Depositary Share (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 12/22/2022
|
7 Drug Stocks That Will Soar in 2023
- Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.
- 12/22/2022
|
Why Is Verona Pharma (VRNA) Stock Up 34% Today?
- Verona Pharma (NASDAQ: VRNA ) stock is rising higher on Tuesday after the company released results from a Phase 3 clinical trial. The big news here is the company's Phase 3 ENHANCE-1 trial meeting its primary endpoint.
- 12/20/2022
|
Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High
- Verona said Tuesday its drug significantly improved lung function in patients with COPD, and VRNA stock skyrocketed to a four-year high. The post Top-Notch Verona Pharma Scores A Win In COPD — And Hits A Four-Year High appeared first on Investor's Business Daily.
- 12/20/2022
|
Verona Pharma's stock jumps 39% after sharing positive data for its COPD drug
- U.S.-listed shares of Verona Pharma Plc VRNA, +2.74% rallied about 39% in premarket trading on Tuesday after the company said a Phase 3 clinical trial evaluating nebulized ensifentrine as a treatment for chronic obstructive pulmonary disease met the primary and secondary endpoints. The data "support our belief that ensifentrine will change the treatment paradigm for COPD," Verona CEO David Zaccardelli said in a news release.
- 12/20/2022
|
Lucid Is Revving Up, but This Nasdaq Stock Is Jumping Even More
- Investors hoped for a rebound in the stock market, but they might have to settle for gains in these two stocks.
- 12/20/2022
|
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
- LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized ensifentrine on Tuesday, December 20, 2022. The Company will host an investment community webcast and conference call at 8:30 a.m. EST / 1:30 p.m. GMT to discuss these data.
- 12/19/2022
|
Here's Why Verona Pharma PLC American Depositary Share (VRNA) is a Great Momentum Stock to Buy
- Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 12/05/2022
|
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going
- Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 11/15/2022
|
Verona Pharma plc (VRNA) Q3 2022 Earnings Call Transcript
- Verona Pharma plc (NASDAQ:VRNA ) Q3 2022 Earnings Conference Call November 9, 2022 9:00 AM ET Company Participants David Zaccardelli – Chief Executive Officer Mark Hahn – Chief Financial Officer Kathy Rickard – Chief Medical Officer Chris Martin – Senior Vice President-Commercial Conference Call Participants Suji Jeong – Jefferies Boobalan Pachaiyappan – H.C. Wainwright Tom Shrader – BTIG Operator Welcome to Verona Pharma's, Third Quarter 2022 Financial Results and Operating Highlights Conference Call.
- 11/09/2022
|
Verona Pharma Announces November 2022 Investor Conference Participation
- LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following conferences in November 2022:
- 11/02/2022
|
3 Small-Cap Pharma Stocks For A 2022 Melt-Up
- This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.
- 10/27/2022
|
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 10/26/2022
|
Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
- Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrine as maintenance treatment of COPD is expected by end of 2022.
- 09/13/2022
|
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
- LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM ET / 7:00 PM BST.
- 08/29/2022
|
All You Need to Know About Verona Pharma PLC American Depositary Share (VRNA) Rating Upgrade to Strong Buy
- Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 08/09/2022
|
Why Is Verona Pharma (VRNA) Stock Up 76% Today?
- Source: Shutterstock Verona Pharma (NASDAQ: VRNA ) stock is rocketing higher on Tuesday following the release of its latest earnings report and clinical trial results. Starting with that earnings report, the biopharmaceutical company posted earnings per share of -4 cents.
- 08/09/2022
|
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD
- Second quarter 2022 financial results and corporate update Second quarter 2022 financial results and corporate update
- 08/08/2022
|
Verona Pharma PLC American Depositary Share (VRNA) is on the Move, Here's Why the Trend Could be Sustainable
- Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 08/08/2022
|
Best Momentum Stocks to Buy for July 20th
- AN, LAD, and VRNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 20, 2022.
- 07/20/2022
|
Best Momentum Stocks to Buy for July 14th
- LW, VRNA and JBI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2022.
- 07/14/2022
|
New Strong Buy Stocks for July 14th
- CHMG, CQP, VRNA, JBI and SYY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2022.
- 07/14/2022
|
Verona Pharma to Present at Jefferies Healthcare Conference
- LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 PM ET / 6:30 PM BST.
- 05/25/2022
|
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
- Abstract supports ongoing Phase 3 program and planned NDA submission Abstract supports ongoing Phase 3 program and planned NDA submission
- 05/09/2022
|
Verona Pharma Announces May 2022 Investor Conference Participation
- LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:
- 05/04/2022
|
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2022 on Tuesday, May 3, 2022 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
- 04/19/2022
|
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
- Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
- 03/03/2022
|
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 02/17/2022
|
Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
- he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease. The stock is trading at a 75% discount to its high after successful Phase 2b data for Ensifentrine as a maintenance treatment for chronic obstructive respiratory disease.
- 02/03/2022
|
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
- LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting at 7:00 AM EST / 12:00 PM GMT on Monday, January 10, 2022.
- 01/04/2022
|
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2021 Results - Earnings Call Transcript
- Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Verona Pharma Announces November 2021 Investor Conference Participation
- LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021:
- 11/01/2021
|
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on Tuesday, November 9, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
- 10/26/2021
|
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
- Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
- 10/13/2021
|
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
- Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics
- 09/02/2021
|
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
- LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7:00 AM EDT / 12:00 PM BST on Monday, September 13, 2021.
- 08/31/2021
|
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2021 Results - Earnings Call Transcript
- Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- ENHANCE Phase 3 program on track to report top-line data in 2022
- 08/05/2021
|
Verona Pharma Announces August 2021 Virtual Investor Conference Participation
- LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following virtual investor conferences in August 2021:
- 07/27/2021
|
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and six months ended June 30, 2021 on Thursday, August 5, 2021 and host an investment community conference call at 8:30 a.m. EDT / 1:30 p.m. BST to discuss these financial results and provide a corporate update.
- 07/22/2021
|
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
- Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
- 06/13/2021
|
VRNA Stock Price: Over 15% Increase Pre-Market Explanation
- The stock price of Verona Pharma PLC (NASDAQ: VRNA) increased by over 15% pre-market. This is why it happened.
- 06/10/2021
|
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
- LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET.
- 05/25/2021
|
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
- Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity
- 05/04/2021
|
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript
- Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript
- 05/01/2021
|
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
- ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
- 04/29/2021
|
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
- LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine showed that ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group.
- 04/23/2021
|
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
- LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2021 on Thursday, April 29, 2021 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
- 04/21/2021
|
Revisiting Verona Pharmaceuticals
- Today, we take our first new look at Verona Pharmaceuticals in just over a year. The company has advanced its pipeline since then and is well-funded over the near term.
- 02/28/2021
|
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2020 Results - Earnings Call Transcript
- Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2020 Results - Earnings Call Transcript
- 02/26/2021
|
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
- Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints.
- 02/02/2021
|
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
- Non-dilutive capital to provide further financial flexibility Non-dilutive capital to provide further financial flexibility
- 11/23/2020
|
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
- LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020:
- 11/09/2020
|
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
- Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
- 11/01/2020
|
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
- Initiated ENHANCE Phase 3 clinical trials in COPD
- 10/29/2020
|
Verona Pharma plc : Update on AIM Delisting
- LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended Delisting and Cancellation of its Ordinary Shares from Trading on AIM, as announced on September 21, 2020.
- 10/28/2020
|
